Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV log-grade malignant non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 41-47

  Hagenbeek, Anton ^a   Carde, Patrice ^a   Meerwaldt, Jacobus H ^a   Somers, Reinier ^a   Thomas, José ^a   De Bock, Robrecht ^a   Raemaekers, John M ^a   van Hoof, Achiel ^a   De Wolf Peeters, Chris ^a   van Glabbeke, Martine ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; VINCRISTINE;

ADULT; ALOPECIA; ARTICLE; BLOOD DYSCRASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VOMITING;

EID: 0007884202     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.41     Document Type: Article

References (37)

1. Young RC, Longo DL, Glatstein E. et al: The treatment of indolent lymphomas: Watchful waiting V aggressive combined modality treatment. Semin Hematol 25:11-16, 1988
2. Portlock CS: Management of the low-grade non-Hodgkin's lymphomas. Semin Oncol 17:51-59, 1990
3. Lister TA: The management of follicular lymphoma. Ann Oncol 2:131-135, 1991
4. Horning SJ: Treatment approaches to the low-grade lymphomas. Blood 83:881-884, 1994
5. Kimby E, Björkholm M, Gahrton G, et al: Chlorambucil/ prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: A randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 5:67-71, 1994 (suppl 2)
6. Saven A, Emanuele S, Kosty M, et al: 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 86:1710-1716, 1995
7. Solal-Céligny P, Brice P, Brousse N, et al: Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 14:514-519, 1996
8. Gribben JG, Freedman AS, Neuberg D, et al: Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325:1525-1533, 1991
9. Rohatiner AZS, Johnson PWM, Price CGA, et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177-1184, 1994
10. van Besien KW, Khouri IF, Giralt SA, et al: Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: The case for aggressive management. J Clin Oncol 13:1096-1102, 1995
11. Bastion Y, Brice P, Haioun C, et al: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 86:3257-3262, 1995
12. Merigan TC, Sikora K, Breeden JH, et al: Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 299:1449-1453, 1978
13. Gutterman JU, Blumenschein GR, Alexanian R, et al: Leukocyte interferon induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Int Med 93:399-406, 1980
14. Louie AC, Gallagher KG, Sikora K, et al: Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. Blood 58:712-718, 1981
15. Foon KA, Sherwin SA, Abrams PG, et al: Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. N Engl J Med 311:1148-1152, 1984
16. Quesada JR, Hawkins M, Horning S, et al: Collaborative phase I-II study of recombinant DNA-produced leukocyte interferon (clone A) in metastatic breast cancer, malignant lymphoma, and multiple myeloma. Am J Med 77:427-432, 1984
17. Horning SJ, Merigan TC, Krown SE, et al: Human interferon alfa in malignant lymphoma and Hodgkin's disease: Results of the American Cancer Society trial. Cancer 56:1305-1310, 1985
18. Wagstaff J, Loynds P, Crowther D: A phase II study of human rDNA alfa-2 interferon in patients with low grade non-Hodgkin's lymphoma. Cancer Chem Pharmacol 18:54-58, 1986
19. O'Connell MJ, Colgan JP, Oken MM, et al: Clinical trial of recombinant leukocyte A interferon as initial therapy for favorable histology non-Hodgkin's lymphoma and chronic lymphocytic leukemia: An Eastern Cooperative Oncology Group pilot study. J Clin Oncol 4:128-136, 1986
20. Rohatiner AZS, Richards MA, Barnett MJ, et al: Chlorambucil and interferon for low grade non-Hodgkin's lymphoma. Br J Cancer 55:225-226, 1987
21. Chisesi T, Capnist G, Vespignani M, et al: Interferon alpha 2b and chlorambucil in the treatment of non-Hodgkin's lymphoma. Invest New Drugs 5:35-40, 1987
22. Leavitt RD, Ratanatharathorn V, Ozer H, et al: Alfa-2b interferon in the treatment of Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol 14:18-23, 1987
23. Clark RH, Dimitrov NV, Axelson JA, et al: A phase II trial of intermittent leukocyte interferon and high dose chlorambucil in the treatment of non-Hodgkin's lymphoma resistant to conventional therapy. Am J Clin Oncol 12:75-77, 1989
24. Mathé G, Fouillart P, Lapeyraque F: Active immunotherapy of L1210 leukemia applied after the graft of tumour cells. Br J Cancer 23:814-821. 1969
25. Hagenbeek A, Martens ACM: BCG treatment of residual disease in acute leukemia: Studies in a rat model for acute myelocytic leukemia (BNML). Leuk Res 7:547-555, 1983
26. Balkwill FR: Antitumor effects of interferon in animals, in Finter NB, Olham RK (eds): Interferon 4. In Vivo and Clinical Studies. Amsterdam, The Netherlands, Elsevier, 1985, pp 23-45
27. Smalley RV, Andersen JW, Hawkins MJ, et al: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336-1341, 1992
28. Solal-Céligny P, Lepage E, Brousse N, et al: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329:1608-1614, 1993
29. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a Working Formulation for clinical usage. Cancer 49:2112-2135, 1982
30. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
31. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
32. Peto R, Peto J: Asymptotically efficient rank test procedures. J Royal Statist Soc A135:185-206, 1972
33. Cox DR: Regression models and life-tables. J Royal Stat Soc 834:187-220, 1972
34. VanderMolen LA, Steis RG, Duffey PL, et al: Low- versus high-dose interferon alfa-2a in relapsed indolent non-Hodgkin's lymphoma. J Nat Cancer Inst 82:235-238, 1990
35. Andersen JW, Smalley RV: Interferon alfa plus chemotherapy for non-Hodgkin's lymphoma: Five-year follow-up. N Engl J Med 329:1821-1822, 1993
36. Cole BF, Solal-Céligny P, LePage E: Interferon alpha for the treatment of advanced follicular lymphoma: An analysis of quality-of-life adjusted survival. Blood 86:440a, 1995 (abstr; suppl 1)
37. Unterhalt M, Herrmann R, Nahler M, et al: Significant prolongation of disease free survival in advanced low-grade non-Hodgkin lymphomas (NHL) by interferon alpha maintenance. Blood 86:439a, 1995 (abstr; suppl 1)